期刊论文

Effects and mechanism research of astragaloside IV improving insulin resistance of HepG2 cells based on pharmacophore and molecular docking

Tang, B.

中文

中草药

0253-2670

2020

51

1

163-168

10.7501/j.issn.0253-2670.2020.01.022

国家自然科学基金资助项目(81503385) 湖南中医药大学“十三五”一级学科基础医学建设项目.

本校为第一机构

目的观察黄芪甲苷(astragaloside IV,AST IV)改善人肝癌HepG2细胞胰岛素抵抗作用,基于药效团模型相互匹配和分子对接预测和验证AST IV可能作用靶点,探讨AST IV改善胰岛素抵抗机制。方法采用高浓度胰岛素诱导HepG2细胞制备胰岛素抵抗模型,AST IV干预后,检测细胞葡萄糖消耗量,基于药效团模型相互匹配和分子对接预测AST IV可能作用靶点,Western blotting法检测通路相关蛋白表达。结果AST IV干预能显著增加胰岛素抵抗的HepG2细胞葡萄糖消耗量,且效应与盐酸吡格列酮相当;基于药效团模型相互匹配和分子对接预测AST IV作用靶点与酪氨酸磷酸酶1B(PTP1B)相关;Western blotting结果显示,胰岛素抵抗的HepG2...

Objective: To research the effects of astragaloside IV (AST IV) on improving insulin resistance in HepG2 cells, and predict and verify the AST IV possible targets based on pharmacophore model matching and molecular docking. Methods: HepG2 cells insulin resistance model was induced with high concentration insulin. After being interfered by AST IV, the glucose consumption was characterized by glucose test, AST IV possible targets were predicted by pharmacophore model matching and molecular docking, the expressions of related pathway protein were ...